Melatonin use in managing insomnia in children with autism and other neurogenetic disorders - An assessment by the international pediatric sleep association (IPSA)
Fiche du document
- ISIDORE Id: 10670/1.8792d9...
- hal: hal-04598769
- doi: 10.1016/j.sleep.2024.04.008
- PUBMED: 38704869
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.sleep.2024.04.008
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/38704869
info:eu-repo/semantics/OpenAccess
Mots-clés
-bio]Citer ce document
Suresh Kotagal et al., « Melatonin use in managing insomnia in children with autism and other neurogenetic disorders - An assessment by the international pediatric sleep association (IPSA) », HAL SHS (Sciences de l’Homme et de la Société), ID : 10.1016/j.sleep.2024.04.008
Métriques
Partage / Export
Résumé
Though it is widely prescribed for improving sleep of children with autism and other neurogenetic disorders, there is a need for practical guidance to clinicians on the use of melatonin for managing insomnia in this population. Because data were either lacking or inconclusive, a task force was established by the International Pediatric Sleep Association (IPSA) to examine the literature based on clinical trials from 2012 onwards. A summary of evidence pertaining to melatonin's utility and potential side effects, practice-related caveats, and insights for use are published herewith.
